B O O K - American College of Rheumatology

ACR Poster Session A
452. Belimumab, a BLyS-Specific Inhibitor, Reduced Disease Activity,
Flares, and Prednisone Use in Patients with Seropositive SLE:
Combined Efficacy Results from the Phase 3 BLISS-52 and -76
Studies. M. A. Petri 5 , R. A. Levy 3 , J. T. Merrill 7 , S. Navarra 10 , R.
Cervera 2 , R. F. van Vollenhoven 8 , S. Manzi 11 , D. Gladman 9 , A.
Gallacher 1 , L. Pineda 4 , Z. J. Zhong 4 , D. Hough 4 , W. Freimuth 4 ,
R. A. Furie 6 and for the BLISS- 52 and - 76 Study Groups, 1 Hospital
Británico de Buenos Aires, Argentina, 2 Hospital Clinic, Barcelona,
Spain, 3 Hospital Universitário Pedro Ernesto, Rio de Janeiro,
Brazil, 4 Human Genome Sciences, Inc, Rockville, MD, 5 Johns
Hopkins University School of Medicine, Timonium, MD, 6 North
Shore LIJ Health System, Lake Success, NY, 7 Oklahoma Medical
Research Foundation, Oklahoma City, OK, 8 The Karolinska
Institute, Stockholm, Sweden, 9 Toronto Western Hospital,
Toronto, ON, Canada, 10 University of Santo Tomas Hospital,
Manila, Philippines, 11 West Penn Allegheny Health System,
Pittsburgh, PA.
453. BILAG-Measured Improvement in Moderately and Severely
Affected Body Systems in Patients with Systemic Lupus
Erythematosus (SLE) by Epratuzumab: Results from EMBLEM,
a Phase IIb Study. Kenneth C. Kalunian 5 , Daniel J. Wallace 1 ,
Michelle A. Petri 2 , Frederic A. Houssiau 6 , Marilyn C. Pike 3 ,
Brian Kilgallen 4 , Lexy Kelley 4 and Caroline P. Gordon 7 , 1 West
Hollywood, CA, 2 Timonium, MD, 3 Massachusetts General
Hospital, Harvard Medical School, Boston, MA, 4 UCB, Smyrna,
GA, 5 UCSD School of Medicine, La Jolla, CA, 6 Universite
Catholique Louvain, Brussels, Belgium, 7 University of
Birmingham, Birmingham, United Kingdom.
454. Biologics Use in SLE in 7 Centers – Data from the International
Registry for Biologics in SLE (IRBIS). Ronald Van Vollenhoven 4 ,
Søren Jacobsen 9 , Daniel J. Wallace 1 , John G. Hanly 8 , Michelle
A. Petri 2 , David A. Isenberg 10 , Ann E. Clarke 7 , Julia F. Simard 3 ,
Christian A. Pineau 6 , Sasha R. Bernatsky 5 and for the SLICC
Group, 1 West Hollywood, CA, 2 Timonium, MD, 3 Clinical
Epidemiology Unit, Stockholm, Sweden, 4 Karolinska University
Hospital, Stockholm, Sweden, 5 McGill UHC/RVH, Montreal, QC,
Canada, 6 McGill Univ Health Center, Montreal, QC, Canada,
7
Montreal General Hospital, Montreal, QC, Canada, 8 Queen
Elizabeth II Health Services Center, Halifax, NS, Canada,
9
Rigshospitalet - 4242 , Copenhagen, Denmark, 10 UCL Div of
Medicine, London, United Kingdom.
455. Carotid Plaque Area Correlates Better Than Intima Media
Thickness with Cardiovascular Risk Factors and Clinical
Ischemic Heart Disease in Lupus Patients. Lihi Eder, Murray
B. Urowitz, Dominique Ibanez and Dafna D. Gladman, Toronto
Western Hospital, Toronto, ON, Canada.
456. Circulating Pro-Angiogenic Cells Are Reduced in Patients
with SLE Independent of the Presence of Coronary
Artery Calcification. Joshua Baker 1 , Lifeng Zhang 2 , Sotonye
Imadojemu 2 , Alexis Sharpe 2 , Sarita Patil 2 , Jonni Moore 2 ,
Emile R. Mohler III 2 and Joan Marie Von Feldt 3 , 1 University of
Pennsylvania, Philadelphia, PA, 2 University of Pennsylvania,
3
University of Pennsylvania-Philadelphia, Veterans Affairs
Medical Center, Philadelphia, PA.
457. Effect of Belimumab, a B-Lymphocyte Stimulator–Specific
Inhibitor, on Functional Antibodies to Pneumococcal, Tetanus,
and Influenza Vaccines. W. W. Chatham 6 , D. J. Wallace 1 , W.
Stohl 11 , K. Latinis 8 , S. Manzi 10 , J. McCune 9 , D. Tegzová 3 , J.
McKay 5 , H. E. Avila-Armengol 4 , T. O. Utset 7 , Z. J. Zhong 2 , D.
Hough 2 , W. Freimuth 2 , T. S. Migone 2 and for the BLISS- 76 Study
Group, 1 Cedars-Sinai/UCLA, Los Angeles, CA, 2 Human Genome
Sciences, Inc, Rockville, MD, 3 Institute of Rheumatology and
Rheumatological Clinic, Prague, Czech Republic, 4 Instituto
Jalisciense de Investigacion Clinica, Guadalajara, Mexico,
5
Oklahoma Center for Arthritis Therapy & Research, Tulsa, OK,
6
UAB Arthritis Clinical Intervention Program, Birmingham, AL,
7
University of Chicago, IL, 8 University of Kansas Medical Center,
Kansas City, KS, 9 University of Michigan Health System, Ann
Arbor, MI, 10 University of Pittsburgh School of Medicine, PA,
11
USC Keck School of Medicine, Los Angeles, CA.
458. Effect of Systemic Lupus Erythematosus (SLE) on Pregnancy
Outcome: An Analysis of 268 Pregnancies. Chi Chiu Mok and
Ling Yin Ho, Tuen Mun Hospital.
459. Effects of Disease Activity and Use of Antimalarials on the
Risk of Coronary-Artery Calcifications in SLE Patients. Juanita
Romero-Díaz 3 , Florencia Vargas-Worackova 1 , Eric Kimura-
Hayama 2 , Carlos Aguilar-Salinas 3 and Jorge Sanchez-Guerrero 4 ,
1
Instituto Nacional ce Ciencias Medicas y Nutricion Salvador
Zubiran, 2 Instituto Nacional de Cardiologia Ignacio Chavez,
3
Instituto Nacional de Ciencias Medicas y Nutricion Salvador
Zubiran, 4 Instituto Nacional de Ciencias Medicas y Nutricion
Salvador Zubiran, Mexico.
460. Elevated Levels of Plasma Micro-Particles (PMPs) in Systemic
Lupus Erythematosus (SLE) Are Associated with Higher Risk
of Thrombosis. Aisha Lateef 3 , Laurence S. Magder 4 , Jayesh
Jani 2 , Thomas S. Kickler 2 and Michelle A. Petri 1 , 1 Timonium, MD,
2
Johns Hopkins University, 3 National University Health System,
Singapore, Singapore, 4 University of Maryland Medical School.
461. Evaluation of Cardiac Function and Myocardial Damage in
Women with Systemic Lupus Erythematosus (SLE) by Cardiac
MRI. Mala S. Kaul 2 , Han Kim 2 , E. William St Clair 2 and Megan
E. B. Clowse 1 , 1 Duke Univ Med, Durham, NC, 2 Duke University,
Durham, NC.
462. Fulvestrant (Faslodex) an Estrogen Selective Receptor Down
Regulator in the Therapy of Female SLE Patients, One to Two
Year Following Faslodex Study Termination Revealed Mild
Reactivation of the Serologic Parameters and Disease Activity.
Nabih I. Abdou 1 , Virginia Rider 3 and Cindy A. Greenwell 2 , 1 Center
for Rheumatic Disease Allergy & Immunology, Kansas City, MO,
2
Center for Rheumatic Disease Allery & Immunology, Kansas
City, MO, 3 University of Pittsburg, Pittsburg, KS.
463. Hydroxychloroquine Can Interfere with Flow Cytometric
Analysis of Blood Cells from Patients Taking This Medication.
Louise Fraser 1 , Graham H. Mitchell 1 , Shirish Sangle 2 , Lee Meng
Choong 2 , Richard Ellis 1 , Jo Spencer 1 and David P. D’Cruz 3 ,
1
Department of Immunobiology, King’s College London, 2 Lupus
Research Unit, St Thomas’ Hospital, 3 St Thomas Hospital,
London, United Kingdom.
464. Immunogenicity of the Quadrivalent Recombinant HPV
Vaccine in Female Systemic Lupus Erythematosus Patients
Aged 9 to 26 Years. Arzu Soybilgic 2 , Karen Onel 1 , Tammy O.
Utset 1 , Kenneth A. Alexander 1 and Linda Wagner-Weiner 1 , 1 Univ
of Chicago, Chicago, IL, 2 University of Illinois at Chicago, Chicago,
IL.
178
2010 Program Book